Research and Clinical Trials on Citalopram (Celexa, Cipramil, Seropram)
This list of current clinical research trials on Citalopram (Celexa, Cipramil, Seropram) is followed by a short set of abstracts from the most recent research articles published on the drug.
Citalopram (Celexa, Cipramil, Seropram) Clinical Research Trials
From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Citalopram (Celexa, Cipramil, Seropram).
- Pharmacokinetic and Pharmacodynamic Effects of Escitalopram Depending on Genetic Polymorphisms of the ABCB1-gene
Status: Recruiting, Condition Summary: Pharmacokinetics - Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
Status: Recruiting, Condition Summary: Major Depressive Disorder - EScitalopram PIndolol ONset of Action
Status: Recruiting, Condition Summary: Unipolar Depression - Effects of Intravenous (IV) Citalopram on Emotional Brain Activity in Healthy Young and Elderly Adults
Status: Recruiting, Condition Summary: Healthy Young and Elderly Volunteers - A Study to Evaluate the Effect of Danoprevir/Ritonavir on the Pharmacokinetics of Escitalopram and S-Demethylcitalopram in Healthy Volunteers
Status: Recruiting, Condition Summary: Healthy Volunteer - A Study of RO4995819 in Combination With Citalopram in Healthy Volunteers
Status: Completed, Condition Summary: Healthy Volunteer - Investigation of Tibolone and Escitalopram in Perimenopausal Depression
Status: Recruiting, Condition Summary: Perimenopause Depression - Childhood Adversity, Genetic Polymorphisms and Stress in First Onset Major Depression
Status: Recruiting, Condition Summary: Depression - Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder
Status: Recruiting, Condition Summary: Treatment Outcome - Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder
Status: Recruiting, Condition Summary: Anxiety Disorders; Somatoform Disorders
Get These Clinical Trials as a Newsfeed
Citalopram: 
Current Research Literature on Citalopram (Celexa, Cipramil, Seropram)
Here are abstracts for some of the latest research articles to have appeared on Citalopram (Celexa, Cipramil, Seropram):
Aust N Z J Psychiatry. 2012 Feb; 46(2): 178
Wand AP
Bioprocess Biosyst Eng. 2012 Feb 4;
Wang SZ, Wu JP, Xu G, Yang LR
Lipase-catalyzed remote resolution of the tertiary alcohol, citalopram intermediate (diol acetate), has been achieved. The chiral discrimination was obtained by the Novozym435-catalyzed alcoholysis of the primary hydroxyl ester which was four bonds away from the center. The influence of acyl acceptor structure and the organic solvents on the reaction rate and enantioselectivity were investigated. Based on the thermodynamic analysis, the difference of activation free energy between the two enantiomers which dominated the enantioselectivity was significantly affected by the organic solvents, while the acyl acceptor showed less effect. In addition, the enantiomer discrimination was driven by both the difference of activation enthalpy and activation entropy. The thermodynamic analysis provides further insights into the prediction and optimization of enantioselectivity and reaction rate in remote resolution.
Obsessive compulsive disorder.
Clin Evid (Online). 2012; 2012:
Soomro GM
Obsessions or compulsions that cause personal distress or social dysfunction affect about 1% of adult men and 1.5% of adult women. About half of adults with obsessive compulsive disorder (OCD) have an episodic course, whereas the other half have continuous problems. Prevalence in children and adolescents is 2.7%. The disorder persists in about 40% of children and adolescents at mean follow-up of 5.7 years. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of initial treatments for obsessive compulsive disorder in adults? What are the effects of initial treatments for obsessive compulsive disorder in children and adolescents? What are the effects of maintenance treatment for obsessive compulsive disorder in adults? What are the effects of maintenance treatment for obsessive compulsive disorder in children and adolescents? What are the effects of treatments for obsessive compulsive disorder in adults who have not responded to initial treatment with serotonin reuptake inhibitors (SRIs)? We searched: Medline, Embase, The Cochrane Library, and other important databases up to April 2011 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).We found 43 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.In this systematic review we present information relating to the effectiveness and safety of the following interventions: addition of antipsychotics to serotonin reuptake inhibitors, behavioural therapy alone or with serotonin reuptake inhibitors, cognitive therapy or cognitive behavioural therapy (CBT) (alone or with serotonin reuptake inhibitors), electroconvulsive therapy, optimum duration of maintenance treatment, psychosurgery, serotonin reuptake inhibitors (citalopram, clomipramine, fluoxetine, fluvoxamine, paroxetine, or sertraline), and transcranial magnetic stimulation.
Citalopram for agitation in Alzheimer's disease: Design and methods.
Alzheimers Dement. 2012 Feb 1;
Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, Marano C, Pelton G, Frangakis C, Rabins PV, Munro CA, Meinert CL, Devanand DP, Yesavage J, Mintzer JE, Schneider LS, Pollock BG, Lyketsos CG,
BACKGROUND: Agitation is one of the most common neuropsychiatric symptoms of Alzheimer's disease (AD), and is associated with serious adverse consequences for patients and caregivers. Evidence-supported treatment options for agitation are limited. The citalopram for agitation in Alzheimer's disease (CitAD) study was designed to evaluate the potential of citalopram to ameliorate these symptoms. METHODS: CitAD is a randomized, double-masked, placebo-controlled multicenter clinical trial, with two parallel treatment groups assigned in a 1:1 ratio and randomization stratified by clinical center. The study included eight recruiting clinical centers, a chair's office, and a coordinating center located in university settings in the United States and Canada. A total of 200 individuals having probable AD with clinically significant agitation and without major depression were recruited for this study. Patients were randomized to receive citalopram (target dose of 30 mg/d) or matching placebo. Caregivers of patients in both treatment groups received a structured psychosocial therapy. Agitation was compared between treatment groups using the NeuroBehavioral Rating Scale and the AD Cooperative Study- Clinical Global Impression of Change, which are the primary outcomes. Functional performance, cognition, caregiver distress, and rates of adverse and serious adverse events were also measured. CONCLUSION: The authors believe the design elements in CitAD are important features to be included in trials assessing the safety and efficacy of psychotropic medications for clinically significant agitation in AD.
Chemosphere. 2012 Jan 31;
Gottschall N, Topp E, Metcalfe C, Edwards M, Payne M, Kleywegt S, Russell P, Lapen DR
Dewatered municipal biosolids (DMBs) were applied to a field at a rate of ∼22Mgdwha(-1) in October 2008. Pharmaceuticals and personal care products (PPCPs) were monitored in groundwater, tile drainage, soil, DMB aggregates incorporated into the soil post-land application, and in the grain of wheat grown on the field for a period of ∼1year following application. Over 80 PPCPs were analyzed in the source DMB. PPCPs selected for in-depth monitoring included: antibiotics (tetracyclines, fluoroquinolones), bacteriocides (triclosan, triclocarban), beta-blockers (atenolol, propranolol, metaprolol), antidepressants (fluoxetine, citalopram, venlafaxine, sertraline), antifungals (miconazole), analgesics (acetaminophen, ibuprofen) and anticonvulsants (carbamazepine). PPCPs in tile were observed twice, ∼3weeks and 2months post-application. Of all PPCPs measured in tile drainage, only carbamazepine, ibuprofen, acetaminophen, triclosan, triclocarban, venlafaxine, and citalopram were detected (5-74ngL(-1)). PPCPs were not detected in groundwater >2m depth below the soil surface, and concentrations above detection limits at 2m depth were only observed once just after the first rain event post-application. In groundwater, all compounds found in tile, except carbamazepine, acetaminophen and citalopram, were detected (10-19ngL(-1)). PPCPs were detected in DMB aggregates incorporated in soil up to 1year post-application, with miconazole and fluoxetine having the lowest percent reductions over 1year (∼50%). For several compounds in these aggregates, concentration declines were of exponential decay form. No PPCPs were detected in the grain of wheat planted post-application on the field. No PPCPs were ever detected in water, soil or grain samples from the reference plot, where no DMB was applied.
